Overview

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, two-part, randomized, double blind, placebo controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetics of STI-1558 administered orally to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Sorrento Therapeutics, Inc.